Browse > Article
http://dx.doi.org/10.7314/APJCP.2014.15.19.8429

Prognostic Significance of Circulating Tumor Cells in Small-Cell Lung Cancer Patients: a Meta-analysis  

Zhang, Jiao (Department of Interventional Therapy, Key Laboratory of Cancer Prevention and Therapy, National Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital)
Wang, Hai-Tao (Department of Interventional Therapy, Key Laboratory of Cancer Prevention and Therapy, National Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital)
Li, Bao-Guo (Department of Interventional Therapy, Key Laboratory of Cancer Prevention and Therapy, National Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital)
Publication Information
Asian Pacific Journal of Cancer Prevention / v.15, no.19, 2014 , pp. 8429-8433 More about this Journal
Abstract
Circulating tumor cells (CTCs) are believed to be particularly important and a reliable marker of malignancy. However, the prognostic significance of CTCs detected in patients with small cell lung cancer (SCLC) is still unclear. We therefore aimed to assess the prognostic relevance of CTCs using a meta-analysis. We searched PubMed for relevant studies and statistical analyses were conducted to calculate the hazard ratio (HR) and 95% confidence intervals (CIs) using fixed or random-effect models according to the heterogeneity of included studies. A total of 7 papers covering 440 SCLC patients were combined in the final analysis. The meta-analysis revealed that CTCs were significantly associated with shorter overall survival (HR=1.9; 95%CI: 1.19-3.04; Z=2.67; P<0.0001) and progression-free survival (HR=2.6; 95%CI: 1.9-3.54; Z=6.04; P<0.0001). The results thus suggest that the presence of CTCs indicates a poor prognosis in patients with SCLC. Further well-designed prospective studies are required to explore the clinical applications of CTCs in SCLC.
Keywords
Circulating tumor cells; small-cell lung cancer; overall survival; progress-free survival-meta-analysis;
Citations & Related Records
Times Cited By KSCI : 3  (Citation Analysis)
연도 인용수 순위
1 Albain KS, Crowley JJ, LeBlanc M, et al (1990). Determinants of improved outcome in small-cell lung cancer: an analysis of the 2, 580-patient Southwest Oncology Group data base. J Clin Oncol, 8, 1563-74.
2 Cristofanilli M, Budd GT, Ellis MJ, et al (2004). Circulating tumor cells, disease progression, and survival in metastatic breast cancer. New Engl J Med, 351, 781-91.   DOI   ScienceOn
3 Alix-Panabieres C, Riethdorf S, Pantel K (2008). Circulating tumor cells and bone marrow micrometastasis. Clin Cancer Res, 14, 5013-21.   DOI
4 American Cancer Society (2009). Cancer facts and figures 2009. Atlanta: American Cancer Society.
5 Cohen SJ, Punt CJA, Iannotti N, et al (2008). Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer. J Clin Oncol, 26, 3213-21.   DOI   ScienceOn
6 de Bono JS, Scher HI, Montgomery RB, et al (2008). Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin Cancer Res, 14, 6302-9.   DOI   ScienceOn
7 Foster NR, Mandrekar SJ, Schild SE, et al (2009). Prognostic factors differ by tumor stage for small cell lung cancer. Cancer, 115, 2721-31.   DOI
8 Govindan R, Page N, Morgensztern D, et al (2006). Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database. J Clin Oncol, 24, 4539-44.   DOI   ScienceOn
9 Hiltermann TJN, Pore MM, Van den Berg A, et al (2012). Circulating tumor cells in small-cell lung cancer: a predictive and prognostic factor. Ann Oncol, 23, 2937-42.   DOI   ScienceOn
10 Horner MJ, Ries LAG, Krapcho M (2009). SEER Cancer Statistics Review, 1975-2006, National Cancer Institute. Bethesda, MD. Based on November 2008 SEER submission data, posted to the SEER website.
11 Igawa S, Gohda K, Fukui T, et al (2014). Circulating tumor cells as a prognostic factor in patients with small cell lung cancer. Oncol Lett, 7, 1469.
12 Hou JM, Krebs MG, Lancashire L, et al (2012). Clinical significance and molecular characteristics of circulating tumor cells and circulating tumor microemboli in patients with small-cell lung cancer. J Clin Oncol, 30, 525-32.   DOI
13 Hou JM, Greystoke A, Lancashire L, et al (2009). Evaluation of circulating tumor cells and serological cell death biomarkers in small cell lung cancer patients undergoing chemotherapy. Am J Pathol, 175, 808-16.   DOI
14 Huang J, Wang K, Xu J, et al (2013). Prognostic significance of circulating tumor cells in non-small-cell lung cancer patients: a meta-analysis. PloS one, 8, 78070.   DOI
15 Kato Y, Ferguson TB, Bennett DE et al (1969). Oat cell carcinoma of the lung. A review of 138 cases. Cancer, 23, 517-24.   DOI
16 Krebs MG, Sloane R, Priest L, et al (2011). Evaluation and prognostic significance of circulating tumor cells in patients with non-small-cell lung cancer. J Clin Oncol, 29, 1556-63.   DOI
17 Ma XL, Li YY, Zhang J, et al (2014). Prognostic role of circulating tumor cells in patients with pancreatic cancer: a meta-analysis. Asian Pac J Cancer Prev, 15, 6015.   DOI
18 Ma XL, Xiao ZL, Liu L, et al (2012). Meta-analysis of circulating tumor cells as a prognostic marker in lung cancer. Asian Pac J Cancer Prev, 13, 1137-44.   DOI   ScienceOn
19 Naito T, Tanaka F, Ono A, et al (2012). Prognostic impact of circulating tumor cells in patients with small cell lung cancer. J Thorac Oncol, 7, 512-9.   DOI
20 Normanno N, Rossi A, Morabito A, et al (2014). Prognostic value of circulating tumor cells' reduction in patients with extensive small-cell lung cancer. Lung Cancer, 85, 314-9.   DOI
21 Shi W L, Li J, Du Y J, et al (2013). CK-19 mRNA-positive cells in peripheral blood predict treatment efficacy and survival in small-cell lung cancer patients. Med Oncol, 30, 1-8.
22 Oshita F, Sekiyama A, Suzuki R, et al (2003). Detection of occult tumor cells in peripheral blood from patients with small cell lung cancer by promoter methylation and silencing of the retinoic acid receptor-beta. Oncol Rep, 10, 105-8.
23 Parmar MK, Torri V, Stewart L (1998). Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med, 17, 2815-34.   DOI   ScienceOn
24 Rolle A, Gunzel R, Pachmann U et al (2005). Increase in number of circulating disseminated epithelial cells after surgery for non-small cell lung cancer monitored by MAINTRAC (R) is a predictor for relapse: A preliminary report. World J Surg Oncol, 3, 18.   DOI
25 Siegel R, Naishadham D, Jemal A (2013). Cancer statistics, 2013. Ca-Cancer J Clin, 63, 11-30.   DOI   ScienceOn
26 Takada M, Fukuoka M, Kawahara M et al (2002). Phase III study of concurrent versus sequential thoracic radiotherapy in combination with cisplatin and etoposide for limited-stage small-cell lung cancer: results of the Japan Clinical Oncology Group Study 9104. J Clin Oncol, 20, 3054-60.   DOI   ScienceOn
27 Tanaka F, Yoneda K, Kondo N, et al (2009). Circulating tumor cell as a diagnostic marker in primary lung cancer. Clin Cancer Res, 15, 6980-6.   DOI
28 Wu C, Hao H, Li L, et al (2009). Preliminary investigation of the clinical significance of detecting circulating tumor cells enriched from lung cancer patients. J Thorac Oncol, 4, 30-6.   DOI
29 Turker I, Uyeturk U, Sonmez OU, et al (2013). Detection of circulating tumor cells in breast cancer patients: prognostic predictive role. Asian Pac J Cancer Prev, 14, 1601-7.   DOI
30 Turrisi A T, Kim K, Blum R, et al (1999). Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. New Engl J Med, 340, 265-71.   DOI   ScienceOn
31 Yip D, Harper PG (2000). Predictive and prognostic factors in small cell lung cancer: current status. Lung cancer, 28, 173-85.   DOI   ScienceOn